NICE backs Akcea’s Tegsedi, pipping Alnylam to hATTR okayNICE has recommended that Akcea’s hereditary transthyretin-related amyloidosis (hATTR) treatment Tegsedi be made available on the NHS in Share XNICE backs Akcea’s Tegsedi, pipping Alnylam to hATTR okayhttps://pharmaphorum.com/news/nice-backs-akceas-tegsedi-pipping-alnylam-to-hattr-okay/
Scotland backs Aimovig for migraine after NICE says noPeople suffering from severe migraines in Scotland will be able to get treatment with Amgen and Novartis’ Aimovig Share XScotland backs Aimovig for migraine after NICE says nohttps://pharmaphorum.com/news/scotland-backs-aimovig-for-migraine-after-nice-says-no/
NICE recommends interim funding for Lilly’s breast cancer drugFinal draft guidance from NICE has recommended interim NHS funding for Eli Lilly’s Verzenios (abemaciclib) with fulvestrant, giving Share XNICE recommends interim funding for Lilly’s breast cancer drughttps://pharmaphorum.com/news/nice-recommends-interim-funding-for-lillys-breast-cancer-drug/
NICE backs funding for MSD’s diabetes drug SteglatroNICE has recommended that England’s NHS should routinely fund Merck, Sharpe, and Dohme’s type 2 diabetes drug Steglatro Share XNICE backs funding for MSD’s diabetes drug Steglatrohttps://pharmaphorum.com/news/nice-backs-funding-for-msds-diabetes-drug-steglatro/
The shadow of Brexit on speed of accessNo-one can miss the ongoing saga that is the UK’s exit from the European Union (EU). The uncertainties Share XThe shadow of Brexit on speed of accesshttps://pharmaphorum.com/views-analysis-market-access/the-shadow-of-brexit-on-speed-of-access/
NICE suggests lower threshold for hypertension treatmentThousands more patients could benefit from drugs and treatment for hypertension under new guidance from NICE, which has Share XNICE suggests lower threshold for hypertension treatmenthttps://pharmaphorum.com/news/nice-suggests-lower-threshold-for-hypertension-treatment-embargo/
UK politicians to grill Vertex CEO over CF price drug rowThe CEO of Vertex Pharmaceuticals is to give evidence before influential UK politicians on Thursday, who are investigating Share XUK politicians to grill Vertex CEO over CF price drug rowhttps://pharmaphorum.com/news/uk-politicians-to-grill-vertex-ceo-over-cf-price-drug-row/
Market access roundup: UK HTA shakeups as Brexit fears deepenWith a Brexit deal still out of sight, there have been intensified warnings in the UK about potential Share XMarket access roundup: UK HTA shakeups as Brexit fears deepenhttps://pharmaphorum.com/views-and-analysis/market-access-roundup-uk-hta-shakeups-as-brexit-fears-deepen/
Price cut unlocks NICE nod for Perjeta in post-surgery breast cancerRoche has finally won NICE backing for the use of Perjeta (pertuzumab) to prevent early-stage HER2-positive breast cancer Share XPrice cut unlocks NICE nod for Perjeta in post-surgery breast cancerhttps://pharmaphorum.com/news/price-cut-unlocks-nice-nod-for-perjeta-in-post-surgery-breast-cancer/
